Alkyl-carbon chain length of two distinct compounds and derivatives are key determinants of their anti-Acanthamoeba activities by Mooney, Ronnie et al.
 UWS Academic Portal
Alkyl-carbon chain length of two distinct compounds and derivatives are key
determinants of their anti-Acanthamoeba activities
Mooney, Ronnie;  Masala , Mariana; Martial, Theo; McGinness, Charles; Henriquez, Fiona ;
Williams, Roderick Adenyinka Malcolm
Published in:
Scientific Reports
DOI:
10.1038/s41598-020-62934-8
Published: 14/04/2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication on the UWS Academic Portal
Citation for published version (APA):
Mooney, R., Masala , M., Martial, T., McGinness, C., Henriquez, F., & Williams, R. A. M. (2020). Alkyl-carbon
chain length of two distinct compounds and derivatives are key determinants of their anti-Acanthamoeba
activities. Scientific Reports, 10(1), [6420]. https://doi.org/10.1038/s41598-020-62934-8
General rights
Copyright and moral rights for the publications made accessible in the UWS Academic Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
Take down policy
If you believe that this document breaches copyright please contact pure@uws.ac.uk providing details, and we will remove access to the
work immediately and investigate your claim.
Download date: 29 Jul 2020
1Scientific RepoRtS |         (2020) 10:6420  | https://doi.org/10.1038/s41598-020-62934-8
www.nature.com/scientificreports
Alkyl-carbon chain length of two 
distinct compounds and derivatives 
are key determinants of their anti-
Acanthamoeba activities
Ronnie Mooney, Mariana Masala, theo Martial, charles McGinness, fiona Luisa Henriquez  
& Roderick Adeyinka Malcolm Williams  *
the opportunistic pathogen, Acanthamoeba castellanii is the causative agent for the sight threatening 
infection Acanthamoeba keratitis (AK). it is commonly associated with contact lens wearers, and 
prevalence is increasing at an alarming rate due to an inadequate preventive strategy to protect the 
lens from this protist. This problem is compounded by the lack of an effective acanthamoebocide, 
particularly with cysticidal activity in the contact lens solutions. We have used cytotoxicity assays 
and a variety of biophysical approaches to show that two molecules with tails made of alkyl carbon, 
alkylphosphocholines (APCs) and quaternary ammonium compounds (QACs) had significant 
chain-length dependent efficacy against A. castellanii trophozoites, the latter producing death 
via permeabilization, and DNA complexing. QACs were more effective than APCs and had activity 
against cysts. Conversely, the QAC with 12 alkyl carbon chain, was non toxic, its presence increased 
A. castellanii trophozoites biomass and delayed encystation by 96 h. Interestingly, it was unable to 
induce excystation and increased trophozoite sensitivity to APC16. These results present a mono- and 
multi-inhibitor management strategy effective against trophozoites and cysts that may be useful for 
formulating into contact lense cleaning solutions and reducing AK incidence.
Acanthamoeba are free-living protists, existing as active trophozoites and non-replicative cysts characterised by 
double cellulose cell walls1. They have opportunistic tendencies and can cause the diseases, Acanthamoeba kera-
titis (AK), cutaneous acanthamoebiasis (CA) and granulomatous amoebic encephalitis (GAE)2,3. Whilst CA and 
GAE are lethal but rare and affect the skin and CNS, respectively, the non-lethal AK causes severe infection in 
the cornea, threatening sight loss and causing emotional and psychological trauma, described as life-changing 
in patients4. Trophozoites to cysts interconversion and vice versa (encystation and excystation) is induced by 
external environmental cues5,6 and poses significant challenges for curative treatment particularly causing AK 
resurgences and relapses7.
AK cases are increasing and prevalence is high amongst contact lens users8,9. Cases of AK within the UK have 
risen drastically within the last 20 years and continue to do so10. The reason for this upsurge in incidence rates 
does not appear to be as a result of increased lens wearers but is as of yet unknown, likely the result of multiple fac-
tors10. Spatial geographic differences are common with 15 times more cases reported in the UK than the USA11,12, 
and 8 times more in Scotland than England13. These differences are strongly linked with water supply, quality and 
usage12. Indeed, the incidence of AK in contact lens users is believed to be due to rinsing of contact lenses with 
domestic tap water14. Further, the lack of anti-acanthamoebocides in cleaning solutions is another issue. Despite 
the presence of preservative compounds such as polyhexamethylene biguanide used in existing solutions, these 
are ineffective at killing cysts and induce encystation15,16. AK prevention thus requires an improved contact lens 
cleansing formulation for an effective preventive strategy.
The identification of compounds with anti-acanthamoebic properties particularly against cysts is challeng-
ing as individual drugs are mainly ineffective15. Established or experimental drug combinations have multiple 
molecular targets. For example, in the clinic combinations of polyhexamethylene biguanide (PHMB), chlorhex-
idine, propamidine isethionate, dibromopropamidine and hexamidine are used17. Experimental compounds to 
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prevent or delay encystation during treatment with encystment inhibitors specific to encystation metabolic path-
ways e.g. autophagy18,19, serine and cysteine proteases and cellulose biosynthesis20,21. This causes Acanthamoeba 
to persist long enough as the vulnerable trophozoites22,23 and to allow a second cytotoxic agent to exert its 
effect24. The combination of different administration routes has also provided positive outcomes, for example 
topical and systemic administration using topical chlorhexidine 0.06% and propamidine isetionate 0.1% and 
the zwitterionic alkylphosphocholine (APC) called miltefosine25,26. APCs are also effective against kinetoplas-
tids (Trypanosoma and Leishmania), anaerobic parasites (Trichomonas and Entamoeba) and other amoebae 
(Naegleria, as well as Acanthamoeba) trophozoites and cysts, but can induce encystation in Acanthamoeba27–32. 
Structure-activities studies in Leishmania33 and Acanthamoeba29 have demostrated that changes in the physical 
strucure of the APC can increase efficacy. Herein, we present a comparative structure-activity study of cationic 
quaternary ammonium compounds (QACs) and APCs. Our results showed that the alkyl carbon chain lengths 
(14–18 carbons) and overall change of the molecule were the main determinant for their anti-acanthamoebic 
activity against A. castellanii, producing death by leakage and DNA complexing. Efficacy for APCs was lower than 
QACs. One QAC with 12 alkyl carbon chain (QAC12), when used alone against tropohzoites was non toxic. In 
contrast, it was used as an energy substrate, increased biomass and delayed encystation. Conversely, QAC12 in 
combination with APC16 was synergistic against trophozoites likely due to the delay in encystation. The results 
present different strategies for an effective preventive treatment strategy for Acanthamoeba.
Results
Long and short alkyl-carbon chain QAcs have contrasting activities against A. castellanii tro-
phozoites. A. castellanii trophozoites presented contrasting responses to the cationic QACs with alkyl-carbon 
chain lengths ranging from 12–18 (named QAC12-QAC18; Table 1). IC50s from QAC14 to QAC18 increased 
progressively with decreased alkyl-carbon chain lengths (Table 2) with death occurring below their correspond-
ing critical micelle concentration after 96 h (Table 2). QAC18 was the most effective. Leakage of DNA, proteins 
and K+ from A. castellanii trophozoites into the external milieu was noted in QAC18-treated cells (37.5 μg/ml) 
Alkyl carbon QACs APCs
18
16
14
12
Table 1. Structures of QACs and APCs.
Compound Abbreviation No. of carbon CMC (µM) MW (g/mol)
IC50
A. castellanii trophozoites A. castellanii cysts
µg/ml µM µg/ml µM
Dodecyltrimethyl 
ammonium 
bromide
QAC12 12 21300* 308.40 >150 >486 >37.50 >121.60
tetradecyltrimethyl 
ammonium 
bromide
QAC14 14 5600* 336.40 52.80 ± 0.14 156.96 ± 0.12 >37.50 >111.47
hexadecyltrimethyl 
ammonium 
bromide
QAC16 16 1300* 364.50 10.80 ± 0.34 29.63 ± 0.03 19.17 ± 0.56 52.59 ± 0.64
octadecyltrimethyl 
ammonium 
bromide
QAC18 18 200 (800)** 392.50 6.90 ± 0.03 17.58 ± 0.04 15.00 ± 0.34 38.21 ± 0.24
Table 2. IC50s of QACs against A.castellanii. The CMC of QACs collated from *Jalali-Heravi & Konouz, 2003; 
**Quan et al., 2007 (Lukac et al., 2013). Data is mean ± SD; n = 4 independent experiments performed in 
triplicates. Student’s t-test showed significant difference between all treatments for each parasite life cycle stage 
at p < 0.01.
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after 24 h. Concentrations of [K+], [DNA] and [proteins] in spent medium were elevated 3.6-fold (Figs. 1A), 4.1-
fold (Fig. 1B) and 15.1-fold (Fig. 1C) respectively and the extruded DNA and proteins are shown in Fig. 1D,E 
respectively. Concurrently, the QAC18-treated trophozoites became smaller than their untreated counterpart 
in width (4-fold; 7.87 ± 0.93 µm and 29.35 ± 0.23 µm; Fig. 2A,B). Morphometric analysis of QAC18 treated and 
untreated trophozoites of A. castellanii, in in vitro cultures showed changes in mean area (377.93 ± 151.78 µm2 
and 112.24 ± 42.66 µm2), perimeter (84.66 ± 24.34 µm and 42.81. ± 12.20 µm), and volume (1628.80 ± 734.91 µm3 
and 508.44 ± 220.05 µm3), after 24 h treatment, with smaller trophozoites much more abundant in QAC-treated 
cells (Fig. 2D,E respectively). The shrunk trophozoites were calcofluor white negative (data not shown) and sen-
sitive to disintegration by 0.5% SDS (92%; Fig. 2C), suggesting that encystation had not occurred. Failure of the 
shrunk cells to oxidise resazurin after the removal of QAC18 and resuspension in PG medium in a 6 hour incu-
bation assay, suggests that this compounds is toxic; QAC16 was active after 24 h at 18.75 μg/ml while QAC14 was 
active after 24 h at 37.5 μg/ml (Table 3). QAC12 was inactive against A. castellanii trophozoites at up to 150 µg/
ml for up to 96 h and surprisingly, produced a dose-dependent increased biomass which suggested that it was an 
energy substrate (Fig. 3).
Examination of the genomic DNA (gDNA) of shrunk QAC18-treated A. castellanii trophozoites (18.75 µg/
ml) after 96 h, using DNA-agarose gel electrophoresis, the fragmented DNA profile consistent with death via 
apoptosis was not observed (data not shown). However, gDNA of A. castellanii incubated with QAC18 produced 
a dose-dependent compaction judged by a progressively increased absorbance at 260 nm (Fig. 4A). In contrast, 
the interaction of QAC12 with A. castellanii gDNA produced a dose-dependent decreased absorbance at 260 nm 
(Fig. 4B). In control experiments, neither QAC12 nor QAC18 had absorption at the concentrations used in the 
interaction assays.
Figure 1. Extrusion of cytoplasmic constituents of A. castellanii trophozoites to the external milieu after QAC 
treatment. [K+] (A), [DNA] (B) and [proteins] (C) released from 105 A. castellanii trophozoites after treatment 
without (control) and with QAC18 at 37.5 µg/ml for 24 h into spent medium and measured with the Atomic 
Absorption Spectroscopy (A), the Nanodrop at 260 nm (B) by Bradford assay (C) respectively were increased 
3.6-fold, 4.1-fold and 15.1-fold respectively. Data is mean ± SD; n = 4 independent experiments performed in 
triplicates. **Student’s t-test showed significant difference of [DNA], [proteins] and [K+] in the spent media of 
control and QAC18-treated cells at p < 0.01. Extracellular DNA was visualised on 0.75% agarose gel (D), Key: 
Lane 1; DNA ladder, Lane 2; spent media on untreated trophozoites, Lane 3; spent media of QAC18-treated 
trophozoites and extracellular proteins visualised on SDS-PAGE (E). Key; Lane 1; protein ladder, Lane 2; spent 
media of QAC18-treated trophozoites, Lane 3; spent media on untreated trophozoites.
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Figure 2. QAC18 induced a cyst-like morphology in A. castellanii. Acanthamoeba trophozoites (105 cells/ml) 
incubated without (A) with QAC18 at 37.5 µg/ml for 1 h at 25 °C (B) and 0.5% SDS for 30 min (C). QAC18 reduced 
trophozoites sizes from 29.02 ± 0.23 (A) to 7.87 ± 0.93 (B) and disintegrated after 30 min treatment with SDS (C). 
Distribution of the area (µm2) (D), optical volume (µm3) (E) and perimeter length (µm) (F) of trophozoites treated 
for 24 h with (grey bar) and without (black bar) QAC18 assessed using the Holomonitor M4.
Drugs
Drug concentration 
(µg/ml)
Trophozoites Cysts
Hours
1 24 48 72 96 24 48 72
QAC14
37.50 + + + + + + + +
18.75 + + + + + + + +
9.375 + + + + + + + +
QAC16
37.50 − − − − − + − −
18.75 + − − − − + + +
9.375 + + + + + + + +
QAC18
37.50 − − − − − − − −
18.75 + − − − − + − −
9.375 + − − − − + + +
Control 0.0000 + + + + + + + +
Table 3. Back transformation of QAC-treated cysts to trophozoites after drug wash-out. “+”Indicates cells 
reverting back to trophozoites after washout; and capable of oxidizing reduced alamar blue from blue to pink 
after 8 days “−” indicates cell that did not revert to trophozoites after wash out and unable to oxidise reduced 
alamar blue solution
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Long Apcs are toxic to A. castellanii trophozoites. The efficacy of the zwitterionic APCs with differ-
ent alkyl-carbon chain lengths (12–16 carbons) tested against A. castellanii was also dependent on tail length, 
with APC12 and APC16 being the least and most potent with IC50s of 32.30 μg/ml and 7.60 μg/ml, respectively 
(Table 4). The removal of APC16 from treated cells, and incubation in PG medium alone, showed that they were 
Figure 3. QAC12 increased A. castellanii cell density in vitro. Acanthamoeba trophozoites (105 cells/ml) treated 
with 150 µg/ml QAC12 doubly serially diluted to 0.015 µg/ml for 96 h at 25 oC. Cell viability estimated by the 
alamar blue assay and expressed as a percentage showed dose-dependent increase in mean absorbance, a 
measure for cell density, which was significant at 9.38 µg/ml and above, a 23% increase in cell density relative to 
control cells without QAC12 was observed at this concentration, with density peaking at 37.5 μg/ml and above 
(>32% increase). Average cell density of untreated cells is 94% (dashed line). Students t-test p < 0.01 as denoted 
by “*”, data is mean viability ± SD; n = 6 independent experiments.
Figure 4. QAC-DNA interaction. The absorbance of genomic DNA (0.6 µg/ml) extracted from A. castellanii 
trophozoites measured at 260 nm with the Nanodrop after incubating for 15 minutes with 0 μg/ml, 0.6 μg/
ml, 6 μg/ml or 12 μg/ml of QAC12 (A) or QAC16 (B) to give ratios of 1:0, 1:1, 1:10 and 1:20. DNA absorbance 
increased and decreased with increased [QAC18] and [QAC12] respectively. Data is mean absorbance at 260 nm 
± SD; n = 4 independent experiments performed in triplicates. Student’s t-test showed significant difference 
between mean absorbance at 1.1, 1:10 and 1:20 relative to 1:0 at p < 0.01 for QAC18 (A) and QAC12 (B) 
respectively.
Compounds Abbreviation
No of 
carbons
MW IC50 (µM)
CMC value 
(µM)g/mol
Acanthamoeba 
trophozoites µg/ml
Acanthamoeba 
trophozoites µM
Dodecylphosphocholine APC12 12 351.50 32.3 ± 0.45 91.89 ± 0.34 1000.00*
Tetradecylphosphocholine APC14 14 379.50 12.7 ± 0.16 33.47 ± 0.24 120.00*
Hexadecylphosphocholine APC16 16 407.50 7.90 ± 0.26 18.65 ± 0.34 13.00*
Table 4. IC50s of APCs against Acanthamoeba trophozoites. Activity of APCs against Acanthamoeba 
trophozoites incubated with different concentrations of APCs for 72 h and 96 h respectively at 26 °C and 
toxicity determined using alamar blue7. The CMCs for APCs were collated from *Yaseen et al. (2005) 
Biophysical Chemistry 117 263-273 and **Anatrace measurement. N/A- not available Data is mean ± SD; n = 4 
independent experiments performed in triplicates. Student’s t-test showed significant difference between all 
treatments for each parasite at p < 0.01.
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able to oxidise resurzarin after 96 h when treated with up to 37.5 μg/ml, suggesting the compound to be amoe-
bostatic or excystation was occuring (data not shown).
QAC12 delayed encystation. The fact that QAC12 promoted trophozoites growth suggested that it pro-
vided a favourable condition for trophozoites and delayed or stop encystation. The incubation of trophozoites in 
encystment medium, supplemented with 37.5 µg/ml of QAC12 delayed encystation by 96 h (Fig. 5). However, the 
same concentration of QAC12 was unable to induce excystation of matured cysts (data not shown).
QAC12 enhanced sensitivity of trophozoites to APC16 but not QAC18. As QAC12 delayed encys-
tation of A. castellanii trophozoites, we postulated that they would be susceptible to the active QACs and APCs. 
The addition of 37.5 µg/ml or 18.75 µg/ml of QAC12 to QAC18 at concentrations starting from 150 μg/ml doubly 
diluted 12 times to 1.17  μg/ml produced estimated IC50s of 14.6 μg/ml and 11.7 μg/ml respectively, statistically 
significantly different from QAC18 alone in control experiments (IC50 - 6.9 μg/ml; p < 0.01, Fig. 6A).
In contrast, QAC16 combined with APC12 under the same conditions produced shifts from the dose response 
curves of APC16-treated cells (Fig. 6B). The estimated IC50s for APC16 with QAC12 at 37.5 μg/ml and 18.75 μg/
ml were 1.74 μg/ml and 2.03 μg/ml, statistically significantly different from the APC16 only in control exper-
iments (IC50-7.6 μg/ml; p < 0.01, Fig. 6B). Interestingly, the removal of the inhibition of APC16 at concentra-
tions of 3.12 μg/ml, 4.68 μg/ml, 6.25 μg/ml and 9.36 μg/ml with QAC12 (37.5 μg/ml and 18.75 μg/ml) after 96 h 
Figure 5. QAC12 delayed A. castellanii trophozoite-cyst conversion. Acanthamoeba trophozoites (106 cells/ml) 
incubated for up to 192 h in encystment medium inoculated with (grey) and without (black) QAC12 at 25 oC. 
The number of cysts produced estimated microscopically and expressed as a percent of total number of cells, 
trophozoites and cysts. Data are mean ± SD; n = 4 independent experiments performed in triplicates. Student’s 
t-test showed significant difference between % cysts with (grey bars) and without (black bars) QAC12 added at 
p < 0.01.
Figure 6. QAC12 increased APC16 efficacy but not QAC18 efficacy in vitro. Acanthamoeba trophozoites (105 
cells/ml. n = 5/treatment) treated with 150 µg/ml doubly diluted to 1.17 µg/ml of QAC18 (A) or APC16 (B) 
for 96 h at 25 oC without QAC12 (closed square) and with two concentrations of QAC12 – 18.75 μg/ml (open 
circle) and 37.5 μg/ml (closed circle). Cell viability estimated using the alamar blue assay showed the addition of 
QAC12 at both concentrations decreased and increased the potency for QAC18 and APC16 respectively relative 
to the monotherapies. Data are mean estimated viability ± SD; n = 4 independent experiments performed in 
triplicates. IC50s were statistically significant between both QAC18 and APC monotherapies and the combined 
treatment using QAC12 at both concentrations (p < 0.01, A,B).
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were unable to oxidise resazurin, but their counterpart without QAC12 added were viable, suggesting that the 
QAC12-APC16 combination increased trophozoites sensitivity to APC16.
QAcs have cysticidal activities against A. castellanii. Lastly, we observed that QAC16 and QAC18 
and not QAC12 had activity against matured A. castellanii cysts (calcofluor white positive and SDS-resistant 
(0.5%, w/v; Fig. 7A–G) and their estimated IC50s were 19.00 ± 0.03 µg/ml and 15.00 ± 0.06 µg/ml respectively 
after 96 h (Table 2). The cysticidal activity of QAC16 to QAC18 strongly correlated with (a) the alkyl-carbon 
chain lengths (Table 2) and the duration of cell exposure to the inhibitor (Fig. 7H). Like trophozoites, drug treat-
ment resulted in leakage of proteins (Fig. 8A). Proteins concentrations in spent medium of QAC-treated cysts 
increased 6.6-fold and the extruded proteins are shown in Fig. 8B. Further, cyst viability estimated using a linked 
reversion-viability assay (that involved inhibitor removal, incubation of cells in PG medium alone for 7 days to 
Figure 7. Integrity of A. castellanii cyst and cytotoxicity to QACs. Acanthamoeba trophozoites (105 cells/ml) 
incubated in encystment medium for 7 days, stained with calcofluor white for 30 minutes observed with the 
DAPI (A) and DIC (B) filters of the EVOS microscope. Merged image of a single cyst (DIC + calcofluor white 
stained cells, (C) and their respective individual calcofluor white (D) and DIC (E) images. Toxicity of QACs 
to A. castellanii cyst assessed using the trypan blue assay with viable (F) and dead (G) cysts without and with 
respectively, cytosolic blue staining. IC50s of cysts treated with QAC16 (closed square) and QAC18 (open 
square) ranging from 37.5 µg/ml to 0.07 µg/ml for 24, 48 and 72 h respectively (H). Data in (h) is mean ± SD; 
n = 4 independent experiments performed in triplicates. Student’s t-test showed significant difference between 
48 h and 72 h for QAC18 relative to 24 h at p < 0.01. No significant difference was observed for QAC16 at the 
same duration and degree of significance.
Figure 8. Extrusion of cytoplasmic constituents of A. castellanii cysts to the external milieu after QAC 
treatment. Protein (A) released after the incubation of 105 A. castellanii cysts, with (QAC18) and without 
(control) QAC18 at 37.5 µg/ml for 24 h, measured in spent medium using the Bradford assay. Data is mean ± 
SD respectively (A); n = 4 independent experiments performed in triplicates. Student’s t-test showed significant 
difference between mean [proteins] in control and QAC18-treated experiments. **p < 0.01. (B) Extracellular 
proteins were visualised with SDS-PAGE. Key: Lane 1; Protein ladder, Lane 2; spent media form untreated cysts, 
Lane 3; spent medium from QAC18-treated cysts.
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induce excystation and viability estimation via Alamar blue), with QAC18 and QAC16 at 37.5 μg/ml after 24 h and 
48 h respectively and for QAC18 at 18.75 μg/ml after 48 h showed no resurgence or resazurin oxidation (Table 3).
Discussion
APCs and QACs are effective antimicrobials against fungi, bacteria, some protists and also have anti-tumour 
properties. In this study, we have confirmed their toxicity against Acanthamoeba trophozoites34,35, and showed 
that QACs were more effective than their APCs counterpart, perhaps due to the formation of larger micelles 
(QACs, 8.8 ± 0.8 nm; APCs, 5.8 ± 1.0 nm)36. Interestingly, the activities from both compound-types were strongly 
correlated with their alkyl-carbon chain lengths against trophozoites, a key indicator for micellar size and hydro-
phobicity. In addition, we noted that the duration of contact between the compound and the protist was impor-
tant; longer alkyl-chain molecules required shorter contact times (<24 h) than their shorter counterpart. This is 
probably related to the nature of their interaction, with complementary alkyl carbon chains in the protist’s plasma 
membrane. Metabolomics analysis have shown that fatty acids 20–30 carbon atoms long37 in A. castellanii are 
abundant in its plasma membranes, presumably enough for long chain QACs to produce rapid solubilisation and 
death. This supports with similar study in the parasitic protist, Leishmania, where lipidomics analysis showed 
fatty acids with 18–25 alkyl-carbons long to be abundant38 and coincidentally, the shorter APCs and QACs were 
more efficacious. Previously as 1.9 × 1010 of QAC18 molecules have been shown to adhere to per unit surface area 
of the plasma membrane of A. castellanii trophozoites to cause leakage39,40. So, there is a possibility that in our 
study, micelles instead assembled on the surface of the cell, increased permeability and caused leakage of proteins 
and DNA in QAC-treated trophozoites.
Our results have also shown that it is possible that, the cationic but less so their zwitterionic APC counterpart, 
can induce rapid reversal of the net negative charge of the protist plasma membrane to positive, with detrimen-
tal effect as described for fungi41,42 and Leishmania spp.43–45. Finally, the observed DNA compacting caused by 
QAC18 and not QAC12 suggested that QAC had an intracellular target and offered a third death mechanism for 
QACs in A. castellanii41,42,46–48. Unexpectedly, death was not due to apoptosis. The data suggests that QAC18 may 
be complexing with compacted DNA, disrupting the normal cell cycle.
Compounds with activity against Acanthamoba cysts are limited. Our study has shown that the QACs used in 
this study have cysticydal activities and cause death via leaking, possibly emanating from conformational changes 
and weakening of the inter-fibre bonds of the cellulose cell wall. Evidence for this is indirect, and based on the loss 
of calcofluor white staining in QAC18-treated cysts. For example, the loss of the natural auto-fluorescent of car-
boxymethyl cellulose after QAC activity has been linked with conformational changes in cellulose46 and as such, 
QACs are being used to alter the structural conformation of wood cellulose in paper manufacturing49.
Further, we observed that QAC12 promoted A. castellanii trophozoites growth, suggesting a role as an energy 
substrate, as its presence increased trophozoites biomass and delayed encystation by 96 h. Interstingly, the delayed 
encystation of trophozoites with QAC12 made them sensitive to APC16 but less so to QAC18; possibly allow-
ing APC16 to exert its cytotoxicity without the induction of encystation. This is evidenced by the cytostatic to 
cytotoxic switch of APC16 without and with QAC12, respectively. At this stage, the interaction of these mixed 
surfactants with different charges to lower the surface interfacial tension of the molecule, their ease of forming 
micelles (CMCs), molar solubilisation ratio cannot be excluded50,51. More investigations are required to substan-
tiate their involvement.
Finally, we have presented sufficient evidence to show QAC18 alone and QAC12 in combination with APC16 
are efficacious against Acanthamoeba castellanii, trophozotes and cysts, enough for consideration as a preventa-
tive management strategy for cleansing contact lens5,32,34. At present, cytotoxicity information of these mixed 
surfactants provided in this study against human epithelial and corneal cell lines are absent and as such are a 
significant barrier for use as a medical device. However, Polyquad, a QAC, is a preferred preservative in contact 
lens cleaning solutions utilised by a number of manufacturers52. In addition, QAC “neutralizing” agents such as 
β-cyclodextrin and NeutraQuat™ that bind free QACs, have very high neutralisation efficacy, such that their use 
as a post-sterilisation step should be suitable to minimise eye damage negating the use of tap water53,54. In short, 
we propose that combinations of different alkylphosphocholines could be introduced in disinfectant protocols 
as an effective preventative management protocol for contact lens care, to prevent Acanthamoeba contamination 
and protect compliant contact lens users.
Methods
cell lines used in this study. Acanthamoeba castellanii ATCC 50370 trophozoites and cysts were cultured 
in Peptone Glucose (PG) medium and encystment medium55 respectively at 25 °C. Cysts were prepared by incu-
bating trophozoites for 8 days in encystment medium and integrity validated with calcofluor (0.25 µg/ml) assay56 
or sodium dodecyl sulfate (SDS, 0.5% w/v) disintegration assay57 and microscopic observation.
cytotoxicity assay. The compounds used in this study all contained alkyl-carbon chains: three APCs 
[dodecyl-PC (APC12), tetradecyl-PC (APC14) and hexadecyl-PC (APC16)] (Anatrace) and four QACs 
[docdecyl-TMAB (QAC12), tetradecyl-TMAB (QAC14), hexadecyl-TMAB (QAC16) and octadecyl-TMAB 
(QAC18)] (Sigma). All were prepared to a stock concentration of 1 mg/ml and diluted as required by the exper-
imental protocol in the cytotoxicity assays. A. castellanii trophozoites and cysts (at 105 cells/ml) with or without 
APCs or QACs (concentrations ranging from 150 µg/ml doubly diluted to 0.15 µg/ml to a final volume of 100 µl) 
in a 96-well plate were incubated at 25 °C for 96 hours.
For the combined assay, similar concentrations of QAC18 and APC16 were prepared and 18.75 µg/ml and 
37.5 µg/ml of QAC12 added (to a final volume of 100 µl) were added to 105 cells/ml in a 96-well plate and later 
incubated at 25 °C for 96 hours.
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Resazurin (5 mg/ml)58 and trypan blue (0.4 µg/ml)59 were then added to trophozoites and cysts respectively 
after exposed to the compounds and the cell viability estimated from changes in absorbance (at 570 nm and 
595 nm) and microscopically respectively.
For the drug kinetic assay, viability was assessed by the linked Alamar blue-reversion assay. Drug-treated cysts 
were washed with PBS and fresh PG medium was added to allow reversion to trophozoites for 5 days, after which, 
alamar blue was added and viability estimated as described above.
Efficacy was expressed as a percentage of untreated controls for each drug concentration used and the data 
used to calculate the IC50. Cell density was estimated using the modified Neubaur hemocytometer and expressed 
as cells/ml.
isolation of total genomic DnA. Genomic deoxynucleic acids (gDNA) from 106 A.castellanii trophozoites 
(treated with and without QAC) were extracted from cells harvested by centrifugation (850 × g, 10 min), lysed 
with UNSET buffer (8 M urea, 150 µM NaCl, 2% SDS, 1 µM ethylenediaminetetraacetic acid (EDTA), 100 µM 
Tris-HCl, pH 7.5) and the DNA extracted with phenol-chloroform (1:1 v/v). The biphasic suspension with DNA 
enriched on the lower trizol layer was centrifuged (12,000 × g for 15 min, 4 °C) for clear separation and trans-
ferred to a new microcentrifuge tube. The DNA was precipitated with cold ethanol (100%, v/v) and 0.3 M sodium 
acetate, washed twice with 70% (v/v) ethanol (12,000 × g for 10 min, 4 °C), air dried and resuspended in distilled 
water.
Morphometric analysis. A. castellanii trophozoites incubated with and without QAC at a duration deter-
mined by experimental protocol were examined microscopically and their sizes measured using the Open 
Laboratory (Improvision) calibration graticule and the the Holomonitor M4 live cell analyser and Holomonitor 
App Suite. The mean body sizes, area, volume and perimeter and the proportion of cells with a fixed interval were 
determined.
potassium (K+) determination assay. Potassium [K+] concentration in spent medium of A. castellanii 
trophozoites and cysts were harvested as described above, filtered with the 0.22 µm syringe filter and used for [K+] 
determination using the Atomic Absorption Spectrometry (ASS, absorbance 766.5 nm). A K+ standard curve was 
used to convert absorbance values to concentration (expressed as mg/ml).
protein and DnA determination assay. Total protein concentration in cell extract and media of 
QAC-treated and untreated A. castellanii trophozoites and cysts were estimated using the Quick Start Bradford 
Protein Assay (Bio-Rad) as described in the manufacturer’s instructions and the absorbances obtained at 
595 nm using the Tecan Infinite M1000 Pro plate reader and expressed as ng/µl protein using a BSA standard 
curve. QAC18 and PG medium were used in control experiments. Proteins were visualised by SDS-PAGE gel as 
described previously38. DNA concentration in cell extract and media of QAC-treated and untreated A. castellanii 
trophozoites were estimated at 260 nm using the Nanodrop ND-1000 and expressed as ng/µl DNA. DNA was 
visualised with DNA agaraose gel (0.75%) as described previously38.
QAc-DnA interaction assay. The interaction between the gDNA from A. castellanii with QAC12 or 
QAC18 was investigated at DNA:QAC ratios of 1:0, 1:1, 1:10 and 1:20 for 15 min and the concentration of unre-
acted DNA in the complex estimated at 260 nm using the Nanodrop ND-1000 at 260 nm.
Statistical analysis. Descriptive statistics of mean and standard deviation values were used to represent 
data for at least four independent experiments each done in triplicate. To explore differences, between baseline 
and assay characteristics, T-test statistics were calculated with a statistical threshold of significance set at p < 0.01 
or p < 0.05.
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